Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

PD-L1 is upregulated in glioblastoma and supports immunosuppression. We evaluated PD-L1 blockade with durvalumab among glioblastoma cohorts and investigated potential biomarkers.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin Cancer Res

Title: Clinical cancer research : an official journal of the American Association for Cancer Research

Publisher: American Association for Cancer Research (AACR)

ISSN (Electronic): 1557-3265

ISSN (Print): 1078-0432

Publication date (Electronic): June 13 2022

Volume: 28

Issue: 12

Affiliations

[1 ] Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

[2 ] Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, California.

[3 ] Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.

[4 ] Departments of Neurology and Neurosurgery, University of California, San Francisco, San Francisco, California.

[5 ] Department of Neurosurgery, Washington University School of Medicine, St. Louis, Missouri.

[6 ] Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.

[7 ] Department of Neurology, University of California, Los Angeles, Los Angeles, California.

[8 ] Department of Medical Oncology, Austin Health, Melbourne, Australia.

[9 ] Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts.

[10 ] Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.

[11 ] PROMETRIKA, LLC, New York, New York.

[12 ] Ludwig Cancer Research, New York, New York.

[13 ] Translational Medicine Oncology, Early and Early Oncology, R&D, Gaithersburg, Maryland.

[14 ] Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York.

Article

Publisher Item ID: 699268

DOI: 10.1158/1078-0432.CCR-21-4064

PubMed ID: 35395080

SO-VID: 2c5ee75e-a459-441c-9d16-857f0e92561e

History

Data availability:

Comments

Comment on this article

scite_

Cited by 11

See all cited by